Google
OSUR 株価分析 — ORASURE TECHNOLOGIES INC (Healthcare >> Medical Instruments & Supplies)
OSUR に関するよくある質問
OSURのROE（自己資本利益率）は？
ORASURE TECHNOLOGIES INCのROEは-23.96%です。
OSURの配当利回りは？
ORASURE TECHNOLOGIES INCの配当利回りは0.00%です。
OSURの品質スコア（Quality Score）は？
当社のAIはOSURの総合財務品質を100点中8点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
OSURは今が買い時ですか？
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
OSURはどのセクターに属しますか？
ORASURE TECHNOLOGIES INCはHealthcare >> Medical Instruments & Suppliesセクターに分類されます（NASDAQ市場）
OSUR AI Analysis Summary
Our AI summary for OSUR: ORASURE TECHNOLOGIES INC (NASDAQ), Healthcare >> Medical Instruments & Supplies sector. The stock currently trades at a P/E of 0.00, ROE of -23.96%, a dividend yield of 0.00%. Its financial Quality Score stands at 8/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.05
Price
0.08
(2.02%)
Day Change
|
|
|---|
OSUR, ファンダメンタルスコアはnot good ( ファンダメンタル = 8) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.05 |
| PBV / Sector |
0.87 / 3.37
GREAT
|
| Earning Per Share | -1.11 |
| PE / Sector |
N/A / 44.25
|
| PEG or PE/Growth / Sector |
N/A / -1.35
|
| Average 1M Daily Value |
1.46 M
GREAT
|
| Average 1W Daily Value |
1.14 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:17 |
| Symbol | OSUR |
| Name | ORASURE TECHNOLOGIES INC |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NASDAQ |
| Listed Shares | 68.85 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 273.33 / 16,159.14 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 220 East First Street, Bethlehem, PA, United States, 18015
Phone: 610 882 1820
Website: https://www.orasure.com
Employees: 500
Description: OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
